Basilea Pharmaceutica AG provided earnings guidance for the year 2021. Total revenue, including revenue contributions from Cresemba and Zevtera as well as BARDA reimbursements, offsetting ceftobiprole phase 3 development expenses and other revenue contributions, is expected to amount to approximately CHF 148 million (fiscal year 2020: CHF 127.6 million).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.85 CHF | +5.28% | +8.48% | +21.39% |
05-03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
04-09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.39% | 542M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2021